Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 2003

View Archived Issues

Sertraline reported to improve major depression in patients with AD

Sepracor updates status of key clinical development programs

New factor XIIIa inhibitors prepared and tested at Curacyte

Antimitotic drugs in early development at Pfizer

Sumitomo presents new 5-HT reuptake inhibitors/5-HT1A agonists

Novel peripheral BZ receptor ligands with neurotrophic activity claimed by Sanofi-Synthelabo

SCRAS scientists design new inhibitors of protein phosphatases

Radiolabeled Ab fragments and their use as angiogenesis markers in cancer diagnosis and treatment

Neurogen updates pipeline status

Abbott and LigoCyte enter collaboration for antiinflammatory monoclonal antibody

Preliminary PRIMO-CABG results reported

Allos Therapeutics commences rolling NDA submission for RSR-13

Norak acquires ChemFolio compound library

ISTA files second Vitrase NDA

Collaborative Study Group to conduct KRX-101 phase II/III program

Prana selects PBT-2 for development for Alzheimer's disease

New phase II trial evaluates NicVAX in smokers

aaiPharma and CIMA to merge

Small-molecule inhibitors of c-Met pursued at Sugen as potential anticancer agents

Lilly to use Serenex chemoproteomics technologies for screening

Bimosiamose decreases LAR in asthmatics following allergen challenge

Genome Therapeutics expands ramoplanin development program

Design of dual Src/Abl tyrosine kinase inhibitors with antitumor and antimetastatic activity

New agent with dual radiosensitizing and cytotoxic activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...